(VNDA) Vanda Pharmaceuticals - Ratings and Ratios
Sleep-Wake, Antipsychotic, Immunology, Oncology, Neurology
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 70.2% |
| Value at Risk 5%th | 91.3% |
| Relative Tail Risk | -20.89% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.93 |
| Alpha | 32.31 |
| CAGR/Max DD | -0.01 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.512 |
| Beta | 0.612 |
| Beta Downside | 0.751 |
| Drawdowns 3y | |
|---|---|
| Max DD | 57.70% |
| Mean DD | 35.77% |
| Median DD | 39.67% |
Description: VNDA Vanda Pharmaceuticals October 27, 2025
Vanda Pharmaceuticals (NASDAQ: VNDA) is a U.S.–based biopharma that commercializes therapies for high-unmet-need conditions, currently selling HETLIOZ for non-24-hour sleep-wake disorder, Fanapt (iloperidone) for bipolar I and Parkinson’s disease psychosis (plus a long-acting injectable for schizophrenia), and Ponvory for psoriasis and ulcerative colitis.
The pipeline expands the sleep-disorder franchise (HETLIOZ for jet-lag, insomnia, delayed-sleep-phase disorder, autism-related sleep disturbances, and pediatric Non-24) and adds a LAI version of Fanapt for schizophrenia, Bysanti (acute bipolar I, schizophrenia, major depressive disorder), and Tradipitant (NK-1R antagonist for gastroparesis, motion sickness, atopic dermatitis). Additional candidates include Imsidolimab (IL-36R antagonist for generalized pustular psoriasis), VTR-297 (HDAC inhibitor for hematologic malignancies), VQW-765 (nicotinic receptor partial agonist for performance anxiety), and a suite of CFTR modulators, antisense oligonucleotides, and other small-molecule programs.
According to the most recent 10-K (FY 2023), Vanda reported $236 million in total revenue, driven primarily by HETLIOZ ($126 million) and Fanapt ($84 million). The company ended FY 2023 with $315 million in cash, cash equivalents, and short-term investments, providing ~2 years of runway at current burn rates. R&D expense was $115 million, reflecting accelerated development of the LAI and sleep-disorder indications.
Key sector drivers that could materially affect Vanda’s outlook include: (1) the global sleep-disorder market, projected to grow at a CAGR of ~6 % through 2030, expanding the addressable pool for HETLIOZ-related indications; (2) continued strong investor appetite for specialty biotech firms with late-stage pipelines, as evidenced by a 12-month average forward P/E of ~30 for comparable peers; and (3) potential reimbursement pressure on specialty psychotropic drugs, which could compress margins for Fanapt if formulary status changes.
If you want a data-rich, objective assessment of VNDA’s valuation metrics and scenario analysis, a quick look at ValueRay’s analyst toolkit can help you benchmark the stock against peers and test sensitivity to key assumptions.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-84.2m TTM) > 0 and > 6% of Revenue (6% = 12.7m TTM) |
| FCFTA -0.14 (>2.0%) and ΔFCFTA -10.98pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 117.7% (prev 179.9%; Δ -62.16pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.14 (>3.0%) and CFO -81.8m > Net Income -84.2m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.12 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (58.9m) change vs 12m ago 1.05% (target <= -2.0% for YES) |
| Gross Margin 93.61% (prev 91.64%; Δ 1.97pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 34.03% (prev 29.59%; Δ 4.45pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -77.37 (EBITDA TTM -101.5m / Interest Expense TTM -1.40m) >= 6 (WARN >= 3) |
Altman Z'' -1.79
| (A) 0.42 = (Total Current Assets 367.5m - Total Current Liabilities 117.9m) / Total Assets 601.1m |
| (B) -0.42 = Retained Earnings (Balance) -253.6m / Total Assets 601.1m |
| (C) -0.17 = EBIT TTM -108.5m / Avg Total Assets 623.1m |
| (D) -1.87 = Book Value of Equity -253.0m / Total Liabilities 135.1m |
| Total Rating: -1.79 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 15.91
| 1. Piotroski 1.50pt |
| 2. FCF Yield -71.81% |
| 3. FCF Margin -39.11% |
| 4. Debt/Equity 0.01 |
| 5. Debt/Ebitda 0.63 |
| 6. ROIC - WACC (= -25.40)% |
| 7. RoE -16.82% |
| 8. Rev. Trend -51.19% |
| 9. EPS Trend -79.01% |
What is the price of VNDA shares?
Over the past week, the price has changed by +1.81%, over one month by +40.63%, over three months by +42.11% and over the past year by +44.23%.
Is VNDA a buy, sell or hold?
- Strong Buy: 1
- Buy: 1
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the VNDA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11.8 | 74.1% |
| Analysts Target Price | 11.8 | 74.1% |
| ValueRay Target Price | 6.9 | 2.5% |
VNDA Fundamental Data Overview December 19, 2025
P/E Forward = 103.0928
P/S = 1.9005
P/B = 0.8433
P/EG = -2.42
Beta = 0.688
Revenue TTM = 212.1m USD
EBIT TTM = -108.5m USD
EBITDA TTM = -101.5m USD
Long Term Debt = 10.9m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 4.27m USD (from shortTermDebt, last fiscal year)
Debt = 6.23m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -63.8m USD (from netDebt column, last quarter)
Enterprise Value = 115.5m USD (403.0m + Debt 6.23m - CCE 293.8m)
Interest Coverage Ratio = -77.37 (Ebit TTM -108.5m / Interest Expense TTM -1.40m)
FCF Yield = -71.81% (FCF TTM -83.0m / Enterprise Value 115.5m)
FCF Margin = -39.11% (FCF TTM -83.0m / Revenue TTM 212.1m)
Net Margin = -39.70% (Net Income TTM -84.2m / Revenue TTM 212.1m)
Gross Margin = 93.61% ((Revenue TTM 212.1m - Cost of Revenue TTM 13.6m) / Revenue TTM)
Gross Margin QoQ = 94.75% (prev 91.47%)
Tobins Q-Ratio = 0.19 (Enterprise Value 115.5m / Total Assets 601.1m)
Interest Expense / Debt = 56.59% (Interest Expense 3.52m / Debt 6.23m)
Taxrate = 20.44% (-5.80m / -28.4m)
NOPAT = -86.4m (EBIT -108.5m * (1 - 20.44%)) [loss with tax shield]
Current Ratio = 3.12 (Total Current Assets 367.5m / Total Current Liabilities 117.9m)
Debt / Equity = 0.01 (Debt 6.23m / totalStockholderEquity, last quarter 466.0m)
Debt / EBITDA = 0.63 (negative EBITDA) (Net Debt -63.8m / EBITDA -101.5m)
Debt / FCF = 0.77 (negative FCF - burning cash) (Net Debt -63.8m / FCF TTM -83.0m)
Total Stockholder Equity = 500.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -14.01% (Net Income -84.2m / Total Assets 601.1m)
RoE = -16.82% (Net Income TTM -84.2m / Total Stockholder Equity 500.6m)
RoCE = -21.22% (EBIT -108.5m / Capital Employed (Equity 500.6m + L.T.Debt 10.9m))
RoIC = -17.25% (negative operating profit) (NOPAT -86.4m / Invested Capital 500.6m)
WACC = 8.14% (E(403.0m)/V(409.3m) * Re(8.27%) + (debt cost/tax rate unavailable))
Discount Rate = 8.27% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.16%
Fair Price DCF = unknown (Cash Flow -83.0m)
EPS Correlation: -79.01 | EPS CAGR: -34.57% | SUE: 0.78 | # QB: 0
Revenue Correlation: -51.19 | Revenue CAGR: -4.94% | SUE: -0.15 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.43 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=3
EPS next Year (2026-12-31): EPS=-1.54 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=+33.4% | Growth Revenue=+21.7%
Additional Sources for VNDA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle